In the latest session, Johnson & Johnson (NYSE: JNJ) closed at $155.76 down -0.29% from its previous closing price of $156.21. In other words, the price has decreased by -$0.45 from its previous closing price. On the day, 5797314 shares were traded.
Ratios:
For a deeper understanding of Johnson & Johnson’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.56. For the most recent quarter (mrq), Quick Ratio is recorded 0.91 and its Current Ratio is at 1.16. In the meantime, Its Debt-to-Equity ratio is 0.44 whereas as Long-Term Debt/Eq ratio is at 0.39.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 13, 2023, Downgraded its rating to Equal Weight and sets its target price to $163 from $170 previously.
On December 01, 2023, UBS Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $167 to $180.
On October 05, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $178.RBC Capital Mkts initiated its Outperform rating on October 05, 2023, with a $178 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 13 ’24 when Broadhurst Vanessa sold 8,891 shares for $162.16 per share. The transaction valued at 1,441,765 led to the insider holds 15,043 shares of the business.
JOHNSON & JOHNSON sold 3,725 shares of JNJ for $96,142 on Feb 16 ’24. The 10% Owner now owns 4,099,575 shares after completing the transaction at $25.81 per share. On Feb 09 ’24, another insider, Taubert Jennifer L, who serves as the EVP, WW Chair, Pharmaceuticals of the company, sold 59,397 shares for $156.27 each. As a result, the insider received 9,281,969 and left with 141,416 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JNJ now has a Market Capitalization of 375.35B and an Enterprise Value of 381.75B. As of this moment, Johnson’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.93, and their Forward P/E ratio for the next fiscal year is 14.17. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.94. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.03 while its Price-to-Book (P/B) ratio in mrq is 5.45. Its current Enterprise Value per Revenue stands at 4.48 whereas that against EBITDA is 16.37.
Stock Price History:
Over the past 52 weeks, JNJ has reached a high of $175.97, while it has fallen to a 52-week low of $144.95. The 50-Day Moving Average of the stock is 159.34, while the 200-Day Moving Average is calculated to be 159.56.
Shares Statistics:
For the past three months, JNJ has traded an average of 6.92M shares per day and 6.99M over the past ten days. A total of 2.41B shares are outstanding, with a floating share count of 2.40B. Insiders hold about 0.16% of the company’s shares, while institutions hold 71.52% stake in the company. Shares short for JNJ as of Feb 29, 2024 were 14.85M with a Short Ratio of 2.15, compared to 12.3M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.62% and a Short% of Float of 0.62%.
Dividends & Splits
According to the company, the forward annual dividend rate for JNJ is 4.76, from 4.70 in the trailing year. Against a Trailing Annual Dividend Yield of 3.01%, it implies a Forward Annual Dividend Yield of 3.06%. The stock’s 5-year Average Dividend Yield is 2.66. The current Payout Ratio is 84.93% for JNJ, which recently paid a dividend on Mar 05, 2024 with an ex-dividend date of Feb 16, 2024. Stock splits for the company last occurred on Jun 13, 2001 when the company split stock in a 2:1 ratio.
Earnings Estimates
There are 15 different market analysts currently analyzing its stock. On average, analysts expect EPS of $2.63 for the current quarter, with a high estimate of $2.77 and a low estimate of $2.44, while EPS last year was $2.41. The consensus estimate for the next quarter is $2.73, with high estimates of $2.84 and low estimates of $2.66.
Analysts are recommending an EPS of between $10.73 and $10.55 for the fiscal current year, implying an average EPS of $10.66. EPS for the following year is $11.04, with 20 analysts recommending between $11.57 and $10.55.
Revenue Estimates
A total of 14 analysts believe the company’s revenue will be $21.4B this quarter.It ranges from a high estimate of $21.8B to a low estimate of $21.11B. As of the current estimate, Johnson & Johnson’s year-ago sales were $24.75B, an estimated decrease of -13.50% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $22.36B, a decrease of -12.40% over than the figure of -$13.50% in the same quarter last year. There is a high estimate of $22.86B for the next quarter, whereas the lowest estimate is $21.89B.
A total of 20 analysts have provided revenue estimates for JNJ’s current fiscal year. The highest revenue estimate was $89.11B, while the lowest revenue estimate was $87.65B, resulting in an average revenue estimate of $88.43B. In the same quarter a year ago, actual revenue was $85.16B, up 3.80% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $90.81B in the next fiscal year. The high estimate is $92.68B and the low estimate is $89.16B. The average revenue growth estimate for next year is up 2.70% from the average revenue estimate for this year.
